The growing prevalence of chronic and infectious diseases has spurred development of the in vitro diagnostics (IVD) market. It is estimated that the global IVD market will reach US$73.9 billion by ...
Revvity, Inc. (NYSE: RVTY), today announced a strategic agreement to commercialize an in vitro diagnostic (IVD) workflow solution for neonatal sequencing, co-developed with Element Biosciences, Inc., ...
(NYSE: RVTY), today announced a strategic agreement to commercialize an in vitro diagnostic (IVD) workflow solution for neonatal sequencing, co-developed with Element Biosciences, Inc., a life ...